Lymphoma News

The FDA announced several regulatory actions the past few weeks.

Intermittent milademetan appeared effective and mitigated dose-limiting hematologic adverse events among patients with advanced solid tumors and lymphomas, according to study results published in Journal of Clinical Oncology.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.

Carl H. June, MD, will receive this year’s AACR Award for Lifetime Achievement in Cancer Research.

Researchers at Cancer Care Alberta and University of Calgary have demonstrated the value of a cancer symptom algorithm in correctly identifying which patients may be at high risk for an unplanned ED visit.

NEW ORLEANS — Reduced left ventricular ejection fraction may be tied to adverse changes in muscle quality among patients with breast cancer or lymphoma undergoing cancer treatment with anthracyclines, a speaker reported.

Polatuzumab vedotin-piiq exhibited a favorable risk-benefit profile as first-line treatment for patients with large B-cell lymphoma, according to an 11-2 vote of the FDA’s Oncologic Drugs Advisory Committee.

Delaying antibiotic treatment beyond 1 hour from developing neutropenic fever did not affect OS among hospitalized patients with cancer, results from a retrospective study showed.

The FDA is aware of 19 cases of squamous cell carcinoma in scar tissue that forms around breast implants, the agency announced today in a safety communication.